Miroslav Palát

M.D. (Hon‘s.) 1989 1st School of Medicine, Charles Univ. Prague,
MBA 2002 Katz Graduate School of Business, Pittsburgh PA.

Miroslav Palát (56), his career opened with 9 years of internal medicine, starting in Czechoslovakia, later 3 years in the UK with the NHS, 2 years in Germany and back in the Czech Republic in 1997.

In 1999 he joined Johnson&Johnson Medical as a Economic Outcomes Specialist. In 2000 he became Director, Clinical and Economic Outcomes Central Europe. Responsibilities periodically covered market access, line management, process management and strategic planning. 2005 – 2008 he developed and implemented EMEA-wide the concept of Strategic Affairs, an integration of the health economic, medical, government and communication functions.

Since 2008 he serves as the president of CzechMed – a trade association of the medical devices industry. He represents the interests of the industry towards government and payers of health care. Herein he ccordinates the association’s activities with similar organisations within the EU via the European trade association Eucomed - MedTechEurope.

As CzechMed celebrates its 20 th anniversary on 22 March 2018, Miroslav Palát , President of the association discusses the past, present and future Czechia was a different place in 1998 when CzechMed was established to represent the medical devices sector. Since then, the economy has grown by an average of 2.5% per year – with the healthcare sector growing at twice that rate – and the country has joined the European Union. As an industry veteran and President of CzechMed, Miroslav Palát has witnessed a period of great change. What difference has EU accession made for the industry? It has enabled free movement of goods which has been of particular benefit to the exporting industry. We have a number of significant medical devices producers for whom the Czech market alone would have been too small to justify establishing a strong presence. Access to the European market is essential. Joining the Single Market also brought us EU rules which, looking back at the Medical Devices Directive, created an easier environment for import and export of products. In the 20-year history of CzechMed, what have been the biggest trends influencing your work? The biggest trends include ease of market entry but, on the other hand, an increasingly difficult environment in terms of obtaining reimbursement. Regulators have become more sophisticated over the course of the past 20 years: one needs to provide a growing volume of documentation in order to secure reimbursement, even for relatively well-established products. Another major trend is the influx of non-European imports which have, one way or another, obtained a CE mark. There are growing volumes of super-cheap products from the far East on the market. Finally, in negotiating and obtaining funding and reimbursement for new technologies, we consistently see very little room to argue on the basis...